Director/PDMR Shareholding

1.

Name of the Issuer:

Hikma Pharmaceuticals PLC

2.

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006):

DTR 3.1.2 R

3.

Name of person discharging managerial responsibilities/director:

Mohammed Ali Khaldoun S Al-Husry

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person:

Nisreen Z. Sh. Oun Alsharifeh (wife)

Tala M. A. KH. Al-Husry (daughter)

Haya M.A. KH. Al-Husry (daughter)

Faisal Sate M. A. KH. Al Husry (son)

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest:

All persons in 3 and 4 and their shareholdings in Hikma (whether direct or indirect)

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares:

Ordinary Shares in Hikma

Ordinary Shares in Darhold Limited, the holding vehicle for shares in Hikma

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them:

DYKB Limited, a British Virgin Islands company which is acting as a holding company for the Al-Husry family.

8.

State the nature of the transaction:

Encumbrance in support of a loan of the shareholdings in Hikma and Darhold belonging to DKYB Limited, on behalf of the persons noted in 3 and 4, above.

9.

Number of shares, debentures or financial instruments relating to shares acquired:

None

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage):

N/A

11.

Number of shares, debentures or financial instruments relating to shares disposed:

None

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage):

N/A

13.

Price per share or value of transaction:

N/A

14.

Date and place of transaction:

London, 27 June 2014

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage):

5,109,748 (2.61%) shares in Hikma comprising:

Directly: 1,109,748 (0.59%)

Indirectly through Darhold limited: 4,000,000 (2.02%)

16.

Date issuer informed of transaction:

27 June 2014

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17.

Date of grant

18.

Period during which or date on which exercisable

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

24.

Name of contact and telephone number for queries

Name of authorised official or issuer responsible for making notification

Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC

Date of notification: 27 June 2014